Understanding heterogeneity in biologic phenotypes of acute respiratory distress syndrome by leukocyte expression profiles

American Journal of Respiratory and Critical Care Medicine

Volumn 200, Issue 1, 2019, Pages 42-50

  Bos, Lieuwe D J ^a   Scicluna, Brendon P ^a   Ong, David S Y ^b   Cremer, Olaf ^b   Van Der Poll, Tom ^a   Schultz, Marcus J ^a,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

Author keywords

ARDS; Personalized medicine; Phenotypes

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BIOLOGICAL MARKER; CREATININE; GAMMA INTERFERON; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 4; NEUTROPHIL COLLAGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; MESSENGER RNA; TRANSCRIPTOME;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; APOPTOSIS; ARTICLE; BIOINFORMATICS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COHORT ANALYSIS; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; LEUKOCYTE; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEPSIS; TRANSCRIPTOMICS; UPREGULATION; BIOLOGY; CLASSIFICATION; GENETICS; INFLAMMATION; INTENSIVE CARE UNIT; MAPK SIGNALING; METABOLISM; MIDDLE AGED; MITOCHONDRION;

AGED; COHORT STUDIES; COMPUTATIONAL BIOLOGY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INTENSIVE CARE UNITS; LEUKOCYTES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; RESPIRATORY DISTRESS SYNDROME, ADULT; RNA, MESSENGER; SEPSIS; TRANSCRIPTOME; UP-REGULATION;

EID: 85065716353     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201809-1808OC     Document Type: Article

References (43)

1. Shankar-Hari M, McAuley DF. Divide and conquer: identifying acute respiratory distress syndrome subphenotypes. Thorax 2017;72: 867-869.
2. Prescott AHC, Calfee CS, Taylor B, Angus DC, Liu VX. Towards smarter lumping and smarter splitting: rethinking strategies for sepsis and ARDS clinical trial design. Am J Respir Crit Care Med 2016;112018: 1-28.
3. Shankar-Hari M, McAuley DF. Acute respiratory distress syndrome phenotypes and identifying treatable traits: the dawn of personalized medicine for ARDS. Am J Respir Crit Care Med 2017;195:280-281.
4. Tonelli AR, Zein J, Adams J, Ioannidis JPA. Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. Intensive Care Med 2014;40:769-787.
5. Laffey JG, Kavanagh BP. Negative trials in critical care: why most research is probably wrong. Lancet Respir Med 2018;6:659-660.
6. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-620.
7. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al.; ARDS Network. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195:331-338.
8. Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS; NHLBI ARDS Network. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med 2018;44: 1859-1869.
9. Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, et al.; MARS Consortium. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 2017;72:876-883.
10. Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS; ARDS Network. Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax 2018;73:439-445.
11. Simonis FD, de Iudicibus G, Cremer OL, Ong DSY, van der Poll T, Bos LD, et al.; MARS Consortium. Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients. Ann Transl Med 2018;6:24.
12. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, et al.; Irish Critical Care Trials Group. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 2018;6:691-698.
13. Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016;47:410-419.
14. Gaudet A, Poissy J, Mathieu D. Time for targeted therapies in acute respiratory distress syndrome? Understanding every single piece of the puzzle. Crit Care Med 2018;46:834-835.
15. Verbist B, Klambauer G, Vervoort L, Talloen W, Shkedy Z, Thas O, et al.; QSTAR Consortium. Using transcriptomics to guide lead optimization in drug discovery projects: lessons learned from the QSTAR project. Drug Discov Today 2015;20:505-513.
16. Sweeney TE, Thomas NJ, Howrylak JA, Wong HR, Rogers AJ, Khatri P. Multicohort analysis of whole-blood gene expression data does not form a robust diagnostic for acute respiratory distress syndrome. Crit Care Med 2018;46:244-251.
17. Bos L, Scicluna B, Van Der Poll T, Ong D, Cremer O, Schultz M. Late breaking abstract - biological phenotypes of ARDS show differential expression of genes involved in oxidative phosphorylation and immunomodulation: an illustration for the need of personalized medicine in ARDS. Eur Respir J 2018;52:OA3292.
18. Klein Klouwenberg PMC, Ong DSY, Bos LDJ, de Beer FM, van Hooijdonk RTM, Huson MA, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 2013;41:2373-2378.
19. van Vught LA, Klein Klouwenberg PMC, Spitoni C, Scicluna BP, Wiewel MA, Horn J, et al.; MARS Consortium. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016;315: 1469-1479.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31: 1250-1256.
21. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al.; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. JAMA 2012;307:2526-2533.
22. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al.; MARS Consortium. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 2017;5:816-826.
23. Kangelaris KN, Prakash A, Liu KD, Aouizerat B, Woodruff PG, Erle DJ, et al. Increased expression of neutrophil-related genes in patients with early sepsis-induced ARDS. Am J Physiol Lung Cell Mol Physiol 2015;308:L1102-L1113.
24. Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014;20:195-203.
25. Rubenfeld GD. Confronting the frustrations of negative clinical trials in acute respiratory distress syndrome. Ann Am Thorac Soc 2015;12: S58-S63.
26. Angus DC, Mira J-P, Vincent J-L. Improving clinical trials in the critically ill. Crit Care Med 2010;38:527-532.
27. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit Care Med 1999; 27:304-312.
28. Iwata K, Doi A, Ohji G, Oka H, Oba Y, Takimoto K, et al. Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis. Intern Med 2010;49: 2423-2432.
29. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008;336: 1006-1009.
30. Meyer NJ, Reilly JP, Anderson BJ, Palakshappa JA, Jones TK, Dunn TG, et al. Mortality benefit of recombinant human interleukin-1 receptor antagonist for sepsis varies by initial interleukin-1 receptor antagonist plasma concentration. Crit Care Med 2018;46: 21-28.
31. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014;5:66-72.
32. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 2011;107:57-64.
33. Kim KJ, Kim KS, Kim NR, Chin HS. Effects of simvastatin on the expression of heme oxygenase-1 in human RPE cells. Invest Ophthalmol Vis Sci 2012;53:6456-6464.
34. Manfredini V, Biancini GB, Vanzin CS, Dal Vesco AMR, Cipriani F, Biasi L, et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem Funct 2010;28:360-366.
35. Gallelli L, Falcone D, Scaramuzzino M, Pelaia G, D'Agostino B, Mesuraca M, et al. Effects of simvastatin on cell viability and proinflammatory pathways in lung adenocarcinoma cells exposed to hydrogen peroxide. BMC Pharmacol Toxicol 2014; 15:67.
36. Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol 1999;20:751-758.
37. Gardai SJ, Whitlock BB, Xiao YQ, Bratton DB, Henson PM. Oxidants inhibit ERK/MAPK and prevent its ability to delay neutrophil apoptosis downstream of mitochondrial changes and at the level of XIAP. J Biol Chem 2004;279:44695-44703.
38. Aoshiba K, Yasui S, Hayashi M, Tamaoki J, Nagai A. Role of p38-mitogen-activated protein kinase in spontaneous apoptosis of human neutrophils. J Immunol 1999;162:1692-1700.
39. Siegl S, Uhlig S. Using the one-lung method to link p38 to proinflammatory gene expression during overventilation in C57BL/6 and BALB/c mice. PLoS One 2012;7:e41464.
40. Damarla M, Hasan E, Boueiz A, Le A, Pae HH, Montouchet C, et al. Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury. PLoS One 2009;4:e4600.
41. Park MS, He Q, Edwards MG, Sergew A, Riches DWH, Albert RK, et al. Mitogen-activated protein kinase phosphatase-1 modulates regional effects of injurious mechanical ventilation in rodent lungs. Am J Respir Crit Care Med 2012;186:72-81.
42. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259-271.
43. Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. Transcriptomic signatures in sepsis and a differential response to steroids: from the VANISH randomized trial. Am J Respir Crit Care Med [online ahead of print] 26 Oct 2018; DOI: 10.1164/rccm.201807-1419OC.